Wang XX, Ma CT, Jiang YX, Ge YJ, Liu FY, Xu WG. Cefoperazone sodium/sulbactam sodium vs piperacillin sodium/tazobactam sodium for treatment of respiratory tract infection in elderly patients. World J Clin Cases 2021; 9(29): 8694-8701 [PMID: 34734047 DOI: 10.12998/wjcc.v9.i29.8694]
Corresponding Author of This Article
Wen-Gang Xu, MD, Chief Physician, Department of Pulmonary Medicine, Shandong Qingdao Hospital of Integrated Traditional Chinese and Western Medicine, No. 5 Jiaxiang Road, Shinan District, Qingdao 266011, Shandong Province, China. jackyxu2021@126.com
Research Domain of This Article
Respiratory System
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Xiao-Xia Wang, Yun-Jie Ge, Department of Cadre Health, Qingdao Municipal Hospital, Qingdao 266011, Shandong Province, China
Cheng-Tai Ma, Department of Emergency Medicine, The Affiliated Hospital of Qingdao University, Qingdao 266011, Shandong Province, China
Yan-Xia Jiang, Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao 266011, Shandong Province, China
Fa-Yun Liu, Wen-Gang Xu, Department of Pulmonary, Shandong Qingdao Hospital of Integrated Traditional Chinese and Western Medicine, Qingdao 266011, Shandong Province, China
Author contributions: Wang XX, Ma CT, and Xu WG designed the research study; Jiang YX and Ge YJ performed the research; Liu FY analyzed the data and wrote the manuscript; all authors have read and approved the final manuscript.
Institutional review board statement: The study was reviewed and approved by the Qingdao Municipal Hospital Institutional Review Board.
Informed consent statement: All study participants provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors have nothing to disclose.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wen-Gang Xu, MD, Chief Physician, Department of Pulmonary Medicine, Shandong Qingdao Hospital of Integrated Traditional Chinese and Western Medicine, No. 5 Jiaxiang Road, Shinan District, Qingdao 266011, Shandong Province, China. jackyxu2021@126.com
Received: June 2, 2021 Peer-review started: June 2, 2021 First decision: June 24, 2021 Revised: July 5, 2021 Accepted: August 9, 2021 Article in press: August 9, 2021 Published online: October 16, 2021 Processing time: 135 Days and 1.2 Hours
ARTICLE HIGHLIGHTS
Research background
Respiratory tract infections in elderly patients are difficult to cure and can easily reoccur, thereby posing a great threat to patient prognosis and quality of life. It is very important to take effective measures to treat these patients as soon as possible.
Research motivation
Elderly patients who have severe pulmonary infections require antibiotic treatment.
Research objectives
This study aimed to determine the therapeutic value and safety of different antibiotics in elderly patients with respiratory tract infection.
Research methods
Seventy-four elderly patients with respiratory tract infection were randomly allocated to a study (n = 37; treated with cefoperazone sodium/sulbactam sodium) or control (n = 37; treated with piperacillin sodium/tazobactam sodium on the basis of routine symptomatic support) group.
Research results
Total effective rate was higher in the study group. There was no significant difference in the incidence of adverse reactions between the groups.
Research conclusions
Piperacillin sodium/tazobactam sodium is better than cefoperazone sodium/ sulbactam sodium in the treatment of respiratory tract infections in elderly patients, and they can reduce the degree of inflammatory reaction, and have a comparable degree of safety.
